Patents by Inventor Andreas Gschwind

Andreas Gschwind has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VEGF-BINDING MOLECULES
    Publication number: 20240141030
    Abstract: VEGF-binding molecules, preferably VEGF-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF-mediated effects on angiogenesis. Nucleic acids encoding VEGF-binding molecules, host cells and methods for preparing same.
    Type: Application
    Filed: January 11, 2024
    Publication date: May 2, 2024
    Inventors: Andreas GSCHWIND, Eric BORGES, Joachim BOUCNEAU, Evelyn DE TAVERNIER, Joost KOLKMAN, Pascal MERCHIERS
  • ANG2-BINDING MOLECULES
    Publication number: 20230203146
    Abstract: Ang2-binding molecules, preferably Ang2-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with Ang2-mediated effects on angiogenesis. Nucleic acids encoding Ang2-binding molecules, host cells and methods for preparing same.
    Type: Application
    Filed: March 17, 2023
    Publication date: June 29, 2023
    Inventors: Rene Georg OTT, Eric BORGES, Andreas GSCHWIND, Joachim BOUCNEAU, Marie-Ange BUYSE, Erik DEPLA, Pascal MERCHIERS, Frederik STEVENAERT
  • VEGF-BINDING MOLECULES
    Publication number: 20220363744
    Abstract: VEGF-binding molecules, preferably VEGF-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF-mediated effects on angiogenesis. Nucleic acids encoding VEGF-binding molecules, host cells and methods for preparing same.
    Type: Application
    Filed: June 21, 2022
    Publication date: November 17, 2022
    Inventors: Andreas GSCHWIND, Eric BORGES, Joachim BOUCNEAU, Evelyn DE TAVERNIER, Joost KOLKMAN, Pascal MERCHIERS
  • Bispecific binding molecules binding to VEGF and Ang2
    Publication number: 20220017642
    Abstract: Bispecifc binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.
    Type: Application
    Filed: September 27, 2021
    Publication date: January 20, 2022
    Inventors: Andreas GSCHWIND, Rene Georg OTT, Joachim BOUCNEAU, Marie-Ange BUYSE, Erik DEPLA
  • Bispecific binding molecules binding to VEGF and Ang2
    Patent number: 11161916
    Abstract: Bispecifc binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: November 2, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gschwind, Rene Georg Ott, Joachim Boucneau, Marie-Ange Buyse, Erik Depla
  • VEGF-BINDING MOLECULES
    Publication number: 20200308267
    Abstract: VEGF-binding molecules, preferably VEGF-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF-mediated effects on angiogenesis. Nucleic acids encoding VEGF-binding molecules, host cells and methods for preparing same.
    Type: Application
    Filed: June 17, 2020
    Publication date: October 1, 2020
    Inventors: Andreas GSCHWIND, Eric BORGES, Joachim BOUCNEAU, Evelyn DE TAVERNIER, Joost KOLKMAN, Pascal MERCHIERS
  • ANG2-BINDING MOLECULES
    Publication number: 20200207845
    Abstract: Ang2-binding molecules, preferably Ang2-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with Ang2-mediated effects on angiogenesis. Nucleic acids encoding Ang2-binding molecules, host cells and methods for preparing same.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 2, 2020
    Inventors: Rene Georg Ott, Eric Borges, Andreas Gschwind, Joachim Boucneau, Marie-Ange Buyse, Erik Depla, Pascal Merchiers, Frederik Stevenaert
  • BISPECIFIC BINDING MOLECULES BINDING TO VEGF AND ANG2
    Publication number: 20200010569
    Abstract: Bispecific binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.
    Type: Application
    Filed: July 18, 2019
    Publication date: January 9, 2020
    Inventors: Andreas GSCHWIND, Rene Georg OTT, Joachim BOUCNEAU, Marie-Ange BUYSE, Erik DEPLA
  • Bispecific binding molecules binding to VEGF and Ang2
    Patent number: 10414828
    Abstract: Bispecific binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: September 17, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gschwind, Rene Georg Ott, Joachim Boucneau, Marie-Ange Buyse, Erik Depla
  • ANG2-BINDING MOLECULES
    Publication number: 20190135907
    Abstract: Ang2-binding molecules, preferably Ang2-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with Ang2-mediated effects on angiogenesis. Nucleic acids encoding Ang2-binding molecules, host cells and methods for preparing same.
    Type: Application
    Filed: July 2, 2018
    Publication date: May 9, 2019
    Inventors: Rene Georg Ott, Eric Borges, Andreas Gschwind, Joachim Boucneau, Marie-Ange Buyse, Erik Depla, Pascal Merchiers, Frederik Stevenaert
  • VEGF-BINDING MOLECULES
    Publication number: 20180201671
    Abstract: VEGF-binding molecules, preferably VEGF-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF-mediated effects on angiogenesis. Nucleic acids encoding VEGF-binding molecules, host cells and methods for preparing same.
    Type: Application
    Filed: December 5, 2017
    Publication date: July 19, 2018
    Inventors: Andreas GSCHWIND, Eric BORGES, Joachim BOUCNEAU, Evelyn DE TAVERNIER, Joost KOLKMAN, Pascal MERCHIERS
  • BISPECIFIC BINDING MOLECULES BINDING TO VEGF AND ANG2
    Publication number: 20170247475
    Abstract: Bispecifc binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.
    Type: Application
    Filed: November 14, 2016
    Publication date: August 31, 2017
    Inventors: Andreas GSCHWIND, Rene Georg OTT, Joachim BOUCNEAU, Marie-Ange BUYSE, Erik DEPLA
  • ANG2-BINDING MOLECULES
    Publication number: 20170107281
    Abstract: Ang2-binding molecules, preferably Ang2-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with Ang2-mediated effects on angiogenesis. Nucleic acids encoding Ang2-binding molecules, host cells and methods for preparing same.
    Type: Application
    Filed: December 21, 2016
    Publication date: April 20, 2017
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Rene Georg OTT, Eric BORGES, Andreas GSCHWIND, Joachim BOUCNEAU, Marie-Ange BUYSE, Erik DEPLA, Pascal MERCHIERS, Frederik STEVENAERT
  • Bispecific binding molecules binding to VEGF and ANG2
    Patent number: 9527925
    Abstract: Bispecific binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: December 27, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gschwind, Rene Georg Ott, Joachim Boucneau, Marie-Ange Buyse, Erik Depla
  • VEGF-BINDING MOLECULES
    Publication number: 20160200806
    Abstract: VEGF-binding molecules, preferably VEGF-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF-mediated effects on angiogenesis. Nucleic acids encoding VEGF-binding molecules, host cells and methods for preparing same.
    Type: Application
    Filed: December 18, 2015
    Publication date: July 14, 2016
    Inventors: Andreas GSCHWIND, Eric BORGES, Joachim BOUCNEAU, Evelyn DE TAVERNIER, Joost KOLKMAN, Pascal MERCHIERS
  • BISPECIFIC BINDING MOLECULES FOR ANTI-ANGIOGENESIS THERAPY
    Publication number: 20140120095
    Abstract: Bispecific binding molecules, in particular immunoglobulin single variable domains such as VHHs and domain antibodies, comprising a VEGF-binding component and a DII4-binding component in one molecule. Pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF- and DII4-mediated effects on angiogenesis. Nucleic acids encoding the bispecific binding molecules, host cells and methods for preparing same.
    Type: Application
    Filed: March 22, 2013
    Publication date: May 1, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Eric BORGES, Andreas GSCHWIND, Joachim BOUCNEAU, Evelyn DE TAVERNIER, Joost KOLKMAN, Pascal MERCHIERS, Diane VAN HOORICK
  • PHARMACEUTICAL COMBINATIONS COMPRISING DUAL ANGIOPOIETIN-2 / DLL4 BINDERS AND ANTI-VEGF AGENTS
    Publication number: 20140093499
    Abstract: The present invention relates to pharmaceutical combinations comprising dual Angiopoietin-2/Dll4 binders and anti-VEGF agents for use in treating diseases like cancer and ocular diseases.
    Type: Application
    Filed: September 26, 2013
    Publication date: April 3, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Andreas GSCHWIND, Anke BAUM
  • PHARMACEUTICAL COMBINATIONS COMPRISING DUAL ANGIOPOIETIN-2 / DLL4 BINDERS AND ANTI-VEGF-R AGENTS
    Publication number: 20140093498
    Abstract: The present invention relates to pharmaceutical combinations comprising dual Angiopoietin-2/DII4 binders and anti-VEGF-R agents for use in treating diseases like cancer and ocular diseases.
    Type: Application
    Filed: September 26, 2013
    Publication date: April 3, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Andreas GSCHWIND, Anke BAUM
  • Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation
    Patent number: 8591903
    Abstract: The present invention relates to the modulation of transactivation of receptor tyrosine kinases by G protein or G protein-coupled receptor (GPCR) mediated signal transduction in a cell or an organism comprising inhibiting the activity of the metalloprotease TACE/ADAM17 and/or the activity of the receptor tyrosine kinase ligand amphiregulin.
    Type: Grant
    Filed: March 9, 2009
    Date of Patent: November 26, 2013
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Axel Ullrich, Andreas Gschwind, Stefan Hart
  • ANG2-BINDING MOLECULES
    Publication number: 20130259859
    Abstract: Ang2-binding molecules, preferably Ang2-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with Ang2-mediated effects on angiogenesis. Nucleic acids encoding Ang2-binding molecules, host cells and methods for preparing same.
    Type: Application
    Filed: March 28, 2013
    Publication date: October 3, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Rene Georg OTT, Eric BORGES, Andreas GSCHWIND, Joachim BOUCNEAU, Marie-Ange BUYSE, Erik DEPLA, Pascal MERCHIERS, Frederik STEVENAERT